---
anonymous_label: OUT-09
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 3575ab26c20297d8b19bca1a3cffd814b338f3bf13cf8556fd44089a4607cb4c
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-09

### Recommendation: Run the Case Evidence Review

You should recommend the **Case Evidence Review**.

**Reasoning:**
Your company is currently experiencing a "false positive" signal. The financial metrics (expansion bookings, shortened cycles) are being driven by sales incentives (bundle pricing) and roadmap promises, not necessarily product value. The usage metrics are deceptive: high-frequency activity is coming from managers (reviewers) rather than the front-line analysts (users), and analysts are abandoning the tool once the initial novelty wears off or when they face internal scrutiny (the "explainability" gap in public sector).

You have a **utility gap**. You know the product is being *used*, but you don't know if it is *effective*. If analysts are overriding or rewriting the plans, PlanPilot isn't a workflow solution; it’s a sophisticated template that still requires manual labor. Scaling this now would be scaling a "leaky bucket."

The **Adoption Quality Sprint** is too superficial; it tracks *that* people return, but not *why* they are returning or if the output is actually used. The **Demand Cleanroom** measures *willingness to pay*, but since you already have the renewals, you need to know if those customers will actually stay. The **Public-Sector pivot** is premature; you don't yet know if the explainability issue is a sector-specific quirk or a fundamental product flaw.

The Case Evidence Review is the only option that audits the **actual work product**. By seeing what was accepted vs. rewritten, you identify exactly where the AI fails. This provides the "ground truth" needed to decide if PlanPilot is a scalable product or a sales gimmick.

***

### The Strongest Reason Against This Recommendation
The Case Evidence Review is **slow and qualitative**. While the board wants a budget lock in 12 days, this review will not provide a statistically significant "green light" for scaling by that deadline. By choosing this, you are effectively telling the CEO and the Board: *"We cannot confidently scale PlanPilot yet because we don't know if it actually works."* This risks bruising the current "commercially disciplined" momentum and may be perceived as the product team slowing down a winning streak.

***

### Observable Evidence That Would Change My Mind
I would pivot to **Scaling PlanPilot Broadly** if you can produce evidence that the "manual overrides" performed by analysts are not corrections of *errors*, but rather *customizations* for specific client preferences.

If the Case Evidence Review reveals that analysts are accepting 80%+ of the core logic and only tweaking the "tone" or "formatting," then the product is fundamentally sound. However, if the evidence shows that analysts are changing the *actual renewal action* (the "what") because they don't trust or cannot explain the logic, scaling would be a catastrophic mistake.
